4D Molecular Therapeutics develops customized gene therapies using a proprietary vector platform optimized through directed evolution, targeting diseases in ophthalmology, pulmonology, and cardiology. Their products aim to provide curative treatments for conditions with significant unmet medical needs, such as reducing the treatment burden for wet age-related macular degeneration.

Cambrian Bio is a clinical-stage drug development company focused on creating therapeutics that target the biological mechanisms of aging to prevent chronic diseases. By collaborating with leading scientists, Cambrian aims to develop effective and safe therapies that extend healthspan and improve patient outcomes.

Deep Longevity employs artificial intelligence to analyze biomarkers of aging, enabling accurate evaluations of biological age. This technology provides essential insights into the aging process, facilitating personalized health interventions and advancements in longevity research.

Exo develops handheld ultrasound devices integrated with artificial intelligence for imaging and therapeutic applications in medical settings. These devices enhance diagnostic accuracy and treatment efficiency, addressing the need for portable and user-friendly imaging solutions in healthcare.

Fountain Life provides a proactive longevity membership that utilizes AI and comprehensive diagnostics to identify health risks early. Their platform offers personalized health plans and therapeutic interventions guided by Longevity Physicians, aiming to extend healthspan and enhance vitality.

Freenome provides a blood‑based early cancer detection platform that uses multiomics profiling—integrating genomics, epigenomics, proteomics, and metabolomics—with AI‑driven analysis to identify cancer at its most treatable stages. The minimally invasive test is designed for routine screening across multiple cancer types and is validated through ongoing clinical programs for use by healthcare providers.

Insilico Medicine utilizes a generative AI platform to streamline drug discovery and development for cancer and age-related diseases, significantly reducing the time and cost associated with bringing new medications to market. The platform integrates multi-omics data analysis and machine learning to identify novel drug targets and predict clinical trial outcomes, enhancing the efficiency of pharmaceutical research.

Juvenescence is a clinical-stage biotech company developing therapies that target core aging mechanisms to prevent age-related diseases and extend healthy lifespan. By utilizing small molecules, biologics, and cell therapies, the company aims to transform aging into a healthier experience, reducing the burden of chronic diseases.

Laronde has developed a programmable RNA platform utilizing Endless RNA™ technology and proprietary nanoparticles to express diverse proteins within the body for therapeutic applications. This approach aims to enhance the treatment of various diseases, including oncology and rare conditions, by providing long-lasting and targeted protein expression.

Life Biosciences is developing cellular rejuvenation therapies that target specific biological mechanisms of aging to reverse and prevent age-related diseases. Their approach aims to provide therapeutic options for chronic conditions that currently lack effective treatments.

LyGenesis is a clinical-stage cell therapy company that utilizes a patient's lymph nodes as bioreactors to grow functioning ectopic organs, addressing the shortage of available organs for transplantation. Their technology allows one donated liver to potentially treat multiple patients with end-stage liver disease through a minimally invasive outpatient procedure.

Senda Biosciences is a therapeutics platform that utilizes Endless RNA™ technology and proprietary programmable nanoparticles to create programmable medicines capable of expressing diverse proteins within the body. This approach aims to enhance the therapeutic potential of RNA for treating various diseases, including oncology and rare conditions, by providing long-lasting and targeted treatment options.

Sigilon Therapeutics develops immune-privileged therapeutic products using encapsulated cell technology to deliver sustained, localized treatment for acute and chronic diseases. This approach minimizes immune rejection and enhances the efficacy of biologic therapies, addressing the limitations of traditional treatment methods.

Tessera Therapeutics is pioneering Gene Writing™, a genome engineering technology that enables precise alterations to the human genome to treat genetic diseases at their source. This platform addresses the need for permanent and potentially curative therapies by delivering therapeutic genetic modifications directly to targeted tissues without the use of viral vectors.

ValoHealth uses AI to analyze large-scale human biological data, uncover causal disease mechanisms, and prioritize novel therapeutic targets. Its closed‑loop chemistry platform then rapidly designs, predicts, and synthesizes small‑molecule candidates, integrating biology, chemistry, and engineering in a collaborative network that accelerates early‑stage drug discovery for pharma, biotech, and academic partners.